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Abstract
Cancer patients are vulnerable to complications of respiratory viruses. This systematic 
review and meta-analysis sought to examine the prevalence of cancer and its associa-
tion with disease severity in patients with novel coronavirus disease 2019 (COVID-19). 
Searches were performed in MEDLINE, EMBASE and ScienceDirect from their incep-
tion until 28 April 2020. Severe disease was considered to encompass cases resulting in 
death or as defined by the primary study authors. Meta-analysis was performed using 
random-effect models. We included 20 studies involving 32,404 patients from China, the 
United Kingdom, the United States, Italy, Singapore, Thailand, France, India and South 
Korea. The pooled prevalence of cancer was 3.50% (95% confidence interval (CI) 1.70 
to 5.80). The pooled prevalence was not moderated by study mean age, proportion of 
females or whether the study was conducted in/outside of China. Patients with cancer 
were more likely to experience severe COVID-19 disease compared to patients without 
cancer (pooled risk ratio 1.76, 95% CI 1.39 to 2.23). Our findings reiterate the need for 
additional precautionary measures to ensure that patients with cancer are not exposed to 
COVID-19, and if they become infected, extra attention should be provided to minimise 
their risk of adverse outcomes.
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Inroduction
The world is battling an immense threat from novel corona virus disease 2019 (COVID-
19). As of 28 April 2020, more than 3.1 million confirmed COVID-19 cases had been 
reported from over 150 countries, among whom over 220,000 had died [1]. Most COVID-
19-related deaths have been attributed to multiple organ failure in older or comorbid 
individuals [2].
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A recent meta-analysis estimated that 2% of patients with COVID-19 had cancer [3]. However, the analysis included only data from China 
and did not evaluate the association of cancer with severe COVID-19 disease. Cancer patients may be more susceptible to COVID-19 than 
healthy individuals due to their high immunosuppressive burden caused by the cancer and anticancer treatments [4]. Improved understand-
ing of the burden of cancer in COVID-19 patients may help to guide clinical management. Hence, in this study, we aimed to estimate the 
prevalence of cancer among COVID-19-infected patients as well as ascertain the association between cancer and disease severity.
Methods
A systematic review was performed in accordance with the recommendations outlined in the PRISMA statement [5] and the Cochrane Hand-
book [6]. We searched MEDLINE, EMBASE and ScienceDirect using the terms ‘comorbidities’ or ‘clinical characteristics’ or ‘epidemiological’ 
and ‘COVID-19’ or ‘Coronavirus’ or ‘2019-nCoV’ or ‘SARS-CoV-2’ or ‘2019 novel coronavirus’ (Supplemental Table S1). The search was last 
updated on April 28, 2020. Further searches were also performed via the websites of the World Health Organization (WHO) and key public 
health institutions in some of the most affected countries (Supplementary Table S2) [1]. The reference lists of identified studies were also 
screened for additional papers. Two reviewers (O.O and R.O) performed article screening and any disagreements were resolved via consen-
sus. Severe disease was considered to encompass cases resulting in death [7] or as defined by the study authors [7]. The quality of individual 
studies was evaluated using the Newcastle–Ottawa Scale (NOS) for non-randomized studies [8]. For each study, two reviewers (R.O and O.O) 
independently collected data, including author details, country (region), mean age, proportion of females, and data on prevalence and disease 
severity. We excluded studies based on family clusters, those focusing solely on deceased individuals and case series involving <10 patients 
or only children. Moreover, reviews, commentaries and editorials were excluded. Furthermore, because a national-based study in China was 
published with data up to February 11, 2020, we excluded all sub-national studies in China that recruited only patients up until that date. 
However, if a study based in China recruited patients beyond this date, they were included. Also, if studies from the same region or hospital 
recruiting patients over the period were present, we selected the report with the larger sample size or more detailed data.
Meta-analysis of prevalence was performed using Freeman–Tukey double arcsine transformation to adjust for variance instability [9]. Owing 
to anticipated between-study heterogeneity, random-effect model was used [6]. Furthermore, pooled risk ratios (RRs) and corresponding 
95% confidence intervals (CIs) were derived to characterise the association between cancer and the occurrence of severe disease. Between-
study heterogeneity was quantified using the I2 statistic [5]. A leave-one-out sensitivity analyses assessed the stability of pooled estimates. 
We applied meta-regression to determine whether the pooled prevalence was moderated by the age of study participants, gender distribu-
tion or location of the study (in/outside of China). All analyses were conducted using Stata SE software version 16 (StataCorp, TX, USA). A 
two-tailed p-value of <0.05 was considered as significant.
Results
The electronic searches retrieved 2,410 citations. Following removal of duplicates and screening of titles and abstracts, 94 articles were 
selected for full text evaluation. Twenty articles were retained after full-text assessment (Figure 1) [10–29]. The included studies were from 
China (n = 10), the United Kingdom (n = 2), South Korea (n = 1), the United States (n = 2), Italy (n = 1), Singapore (n = 1), India (n = 1), France (n 
= 1) and Thailand (n = 1). The studies involved a total of 32,404 patients. The mean age ranged from 40.3 to 75.0 years and 18.0% to 67.1% 
of the patients were females (Table 1). 
Across the studies, the reported prevalence of cancer ranged from 0% to 21.0%. The pooled prevalence was 3.5% (95% CI 1.7 to 5.8%, I2 = 
97.4%) (Figure 2). A leave-one-out sensitivity analysis did not change the results (point estimate ranged from 3% to 4%). There was no signifi-
cant moderation of the pooled prevalence by the participants’ mean age (coefficient = 0.0034, p = 0.247), proportion of females (coefficient 
= 0.0006, p = 0.557) or being conducted in/outside of China (coefficient = −0.009, p = 0.795). Across six studies involving 22,046 patients, 
those with cancer were more likely to experience severe disease compared to patients without cancer (pooled risk ratio (RRpooled) 1.76, 95% 
CI 1.39 to 2.23, I2 = 20.9%) (Figure 3). A leave-one-out analyses did not change the results (the estimates ranged from RRpooled 1.66 (95% CI 
1.27 to 2.17) to 1.82 (95% CI 1.26 to 2.64)).
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Articles retrieved from electronic databases  
(n=2410) 
Duplicates removed (n=385) 
Records after Duplicates removed (n=2025) 
Removed after title and abstract 
screening (n=1931) 
Full text articles screened (n=94) 
Excluded after full text assessment (n=74) 
 
Studies included in review (n=20)  
Figure 1. PRISMA flow chart of studies selection process.
Table 1. Characteristics of included studies.
Study 
No. Author details**
Country  
(location) Hospital
Last follow 
up
Sample 
size
Mean 
age
%  
Female
No. (%) 
with  
cancer 
No. (%) severe diseasea
Cancer 
patients Non-cancer
1. COVID-19 National 
Emergency Response 
Center, Epidemiology 
and Case Manage-
ment Team, Korea 
Centers for Disease 
Control and Preven-
tion [10]
South Korea Korea Centers for 
Disease Control 
and Prevention
February 
14, 2020
28 42.6 46.4 1 (3.6) - -
2. ICNARC [11] United  
Kingdom
England, Wales 
and Northern 
Ireland critical 
care units
March 26, 
2020
775a 60.2 29.1 12 (1.2) - -
3. Wu et al [12] China (Jiangsu) 3 grade IIIA 
hospitals
February 
14, 2020
80 46.1 51.3 1 (1.3) - -
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Table 1. Characteristics of included studies. (Continued)
4. The Novel Corona-
virus Pneumonia 
Emergency Response 
Epidemiology Team 
[13]
China Nationwide February 
11, 2020
20982b - 48.6 107 (0.5) 6 (5.6) 400 (1.9)
5. Zhu et al [14] China (Outside 
of Hubei)
Anhui Province 
ED
February 
20, 2020
32 46.0 53.0 2 (6.3) - -
6. Sun et al [15] Singapore National
Centre for Infec-
tious Diseases
February 
16, 2020
54 42.0 46.3 0 (0.0) - -
7. Chen et al [16] China (Wuhan) Tongji Hospital  February 
28, 2020
274 62.0 38.0 7 (3.0) 5 (71.4) 108 (40.4)
8. Guo et al [17] China (Wuhan) No. 7 Hospital of 
Wuhan
February 
23, 2020
187 58.5 51.3 13 (7.0) - -
9. McMichael et al [18] US (Washing-
ton)
skilled nursing 
facility in King 
County
March 18, 
2020
167 72.0 67.1 15 (9.0) - -
10. Gupta et al [19] India (New 
Delhi)
Sarfdarjung 
hospital
March 19, 
2020
21 40.3 33.3 0 (0.0) - -
11. Klopfenstein et al [20] France NFC hospital March 17, 
2020
54 47.0 67.0 2 (4.0) - -
12. Richardson et al [21] US (New York) Northwell Health 
hospitals
April 4, 
2020
5700 63.0 39.7 320 (6.0) - -
13. Pan et al [22] China (Hubei) Wuhan Hanan 
Hospital, Wuhan 
Union Hospital, 
and Huanggang 
Central Hospital
March 18, 
2020
204
(diges-
tive 
=103)
52.9 52.5 13 (6.37) 4 (50.0)c 33 (34.7)c
14. Pongpirul et al [23] Thailand Bamrasnaradura 
Infectious Dis-
eases Institute
January 31, 
2020
11 61.0 45.5 0 (0) - -
15. Feng et al [24] China  
(Multicentre)
Jinyintan Hos-
pital in Wuhan, 
Shanghai Public 
Health Clinical 
Center in Shang-
hai and Tongling 
People’s Hospital 
in Anhui Province
February 
15, 2020 
476 53.0 43.1 12 (2.5) 7 (58.3) 117 (25.2)
16. Yu et al [5] China  (Wu-
han)
Zhongnan Hos-
pital of Wuhan 
University
February 
17, 2020
1524 - - 12 (0.79) - -
17. Grasselli et al [26] Italy (Lom-
bardy)
72 hospitals March 18, 
2020
1591a 63.0 18.0 81 (8.0) - -
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Table 1. Characteristics of included studies. (Continued)
18. Wang et al [27] China (Wuhan) Renmin Hospital 
of Wuhan Uni-
versity
February 
13, 2020
116 54 42.2 12 (10.3) 11 (91.6) 58/104
19. Chu et al [28] China (Wen-
zhou city)
First Affiliated 
Hospital of Zheji-
ang University 
February 
23, 2020
33a 65.2 33.3 1 (3.0) - -
20. Tomlins et al [29] UK (England) North Bristol 
NHS Trust
March 30, 
2020
95 75.0 37.0 20 (21) 3 (15.0) 17 (22.7)
Figure 2. Forest plot of prevalence of cancer among patients infected with COVID-19. 
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Figure 3. Forest plot of association between cancer and severe disease among COVID-19 patients.
Discussion
The results of our meta-analysis suggest a low prevalence of cancer among COVID-19 patients. However, patients with cancer are 76% more 
likely to experience severe disease compared to those without cancer. This finding is consistent with a recent study which reported that the 
fatality of cancer patients infected with the Middle East respiratory syndrome (MERS)-CoV in 2012 was significantly higher compared to 
patients without cancers [31]. The greater likelihood of severe COVID-19 in patients with cancer may reflect their increased vulnerability to 
developing complications of respiratory viruses [32]. Moreover, many oncology patients often have additional risk factors for severe COVID-
19, such as advanced age and presence of other comorbidities [32].
Our study highlights the need to implement extra precautionary measures (including an awareness campaign) to ensure that patients with 
cancer are not exposed to the virus during the current outbreak and future outbreaks. The development of a COVID-19 vaccine or treatment 
modality may also be useful towards reducing the risk of this vulnerable population. Furthermore, it is imperative that during the current 
COVID-19 outbreak, measures are implemented to minimise interruptions in the provision of essential medical services to cancer patients. 
Of note, as expected given the observational nature of the data, there was evidence of high statistical heterogeneity in the pooled prevalence 
of cancer. This does not necessarily invalidate the findings. Further assessment revealed that the heterogeneity was not entirely explained by 
differences in age or gender distribution among study population. Also, while the included studies originated from a few countries, around 
half were conducted in China which may affect the generalisability of our findings. Hence, further analysis would be necessary as the COVID-
19 pandemic evolves and data from other regions become available. 
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Conclusion
Our findings suggest that COVID-19 patients with cancer are more likely to experience severe disease than those without cancer. This 
emphasises the need to adopt additional precautionary measures to ensure that these vulnerable patients are not exposed to the virus, and 
if they become infected, extra attention should be provided to minimise their risk of adverse outcomes.
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Supplementary material
Table S1. Search strategy.
  1 COVID-19.mp. 
  2 COVID-19.m_titl. 
  3 2019 novel coronavirus.mp. 
  4 2019 novel coronavirus.m_titl. 
  5 2019-nCoV.mp. 
  6 2019-nCoV.m_titl. 
  7 SARS-CoV-2.m_titl. 
  8 SARS-CoV-2.m_titl. 
  9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10 comorbidities.mp. or Comorbidity/ 
11 comorbidity.mp. 
12 clinical characteristics.mp. 
13 clinical characteristics.m_titl. 
14 epidemiological.mp. 
15 epidemiolog*.mp. or Epidemiology/ 
16 epidemiological.m_titl. 
17 epidemiological.mp. 
18 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 
19 9 and 18 
Table S2. Institutional websites of some of the countries searched.
Country Institution Website
Global World Health Organization https://www.who.int/
USA Centers for Disease Control 
and Prevention
https://www.cdc.gov/
China Chinese Centre for Disease 
Control and Prevention
http://www.chinacdc.cn/en/
Spain National Centre of Epidemiol-
ogy, Institute of Health Carlos III
https://www.isciii.es/Paginas/Inicio.aspx
Germany Robert Koch Institute (RKI) https://www.rki.de/EN/Home/homepage_node.html
France Santé Publique France https://www.santepubliquefrance.fr/
Iran Ministry of Health and Medical 
Education
http://www.behdasht.gov.ir/
UK Public Health England https://www.gov.uk/government/organisations/public-health-england
Switzerland Federal Office of Public Health https://www.bag.admin.ch/bag/en/home.html
The Netherlands National Institute of Public 
Health and the Environment
https://www.rivm.nl/en
Canada Public Health Agency of Canada https://www.canada.ca/en/public-health.html
